Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of “Buy” from Brokerages

Enovis Corporation (NYSE:ENOV) has received a consensus recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $47.4286.

ENOV has been the subject of several recent research reports. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Needham & Company LLC lifted their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wells Fargo & Company upgraded shares of Enovis to a “strong-buy” rating in a report on Wednesday. UBS Group reissued a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Finally, Canaccord Genuity Group cut their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders purchased 5,000 shares of company stock valued at $121,983. 2.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ENOV. Arax Advisory Partners bought a new position in Enovis in the 4th quarter valued at $29,000. Farther Finance Advisors LLC raised its stake in shares of Enovis by 42.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Enovis in the 2nd quarter worth about $46,000. Finally, SJS Investment Consulting Inc. grew its position in Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after buying an additional 1,517 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Down 3.7%

ENOV opened at $21.74 on Friday. Enovis has a fifty-two week low of $21.00 and a fifty-two week high of $40.69. The firm has a market capitalization of $1.24 billion, a PE ratio of -1.05 and a beta of 1.46. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The company’s 50-day moving average is $23.26 and its 200 day moving average is $27.54.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.